Flag of the European Union EU Clinical Trials Register Help

Clinical trials for Taxane

The European Union Clinical Trials Register   allows you to search for protocol and results information on:
  • interventional clinical trials that were approved in the European Union (EU)/European Economic Area (EEA) under the Clinical Trials Directive 2001/20/EC
  • clinical trials conducted outside the EU/EEA that are linked to European paediatric-medicine development

    • EU/EEA interventional clinical trials approved under or transitioned to the Clinical Trial Regulation 536/2014 are publicly accessible through the
    Clinical Trials Information System (CTIS).

    The EU Clinical Trials Register currently displays   43881   clinical trials with a EudraCT protocol, of which   7295   are clinical trials conducted with subjects less than 18 years old.   The register also displays information on   18700   older paediatric trials (in scope of Article 45 of the Paediatric Regulation (EC) No 1901/2006).

    Phase 1 trials conducted solely on adults and that are not part of an agreed paediatric investigation plan (PIP) are not publicly available (see Frequently Asked Questions ).  
     
    Examples: Cancer AND drug name. Pneumonia AND sponsor name.
    How to search [pdf]
    Search Tips: Under advanced search you can use filters for Country, Age Group, Gender, Trial Phase, Trial Status, Date Range, Rare Diseases and Orphan Designation. For these items you should use the filters and not add them to your search terms in the text field.
    Advanced Search: Search tools
     
    352 result(s) found for: Taxane. Displaying page 1 of 18.
    1  2  3  4  5  6  7  8  9  Next» Last»»
    EudraCT Number: 2005-004587-23 Sponsor Protocol Number: UZL/MBC SUBE0501 Start Date*: 2005-12-23
    Sponsor Name:UZ Leuven
    Full Title: A belgian multicenter phase II randomized trial in her2 negative metastatic breast cancer evaluating consolidation antiangiogenic therapy with SU11248 after response to taxane chemotherapy induction
    Medical condition: Patients must meet all of the following inclusion criteria in order to be eligible for participation in this study: • Patients with metastatic breast cancer, histologically proven • Patients receiv...
    Disease:
    Population Age: Adults, Elderly Gender: Female
    Trial protocol: BE (Completed)
    Trial results: View results
    EudraCT Number: 2005-004913-14 Sponsor Protocol Number: CEPO906A2203 Start Date*: 2005-08-15
    Sponsor Name:Novartis Pharma Services AG
    Full Title: An open-label Phase I/II dose escalation study evaluating the safety and efficacy of patupilone in patients with advanced ovarian, primary fallopian, or primary peritoneal cancer
    Medical condition: Approximately 75% of women with ovarian cancer present advanced disease. Survival is highly dependent on the stage of disease at the initiation of treatment. Favorable prognostic factors include y...
    Disease:
    Population Age: Adults, Elderly Gender: Female
    Trial protocol: AT (Completed) BE (Completed)
    Trial results: View results
    EudraCT Number: 2016-003996-23 Sponsor Protocol Number: SAKK08/16 Start Date*: 2017-08-29
    Sponsor Name:SAKK
    Full Title: ODM-201 maintenance therapy in patients with metastatic castration resistant prostate cancer (mCRPC) previously treated with one novel hormonal agent first line and nonprogressive disease after sec...
    Medical condition: Metastatic castration resistant prostate cancer
    Disease: Version SOC Term Classification Code Term Level
    20.0 100000004864 10007453 Carcinoma of the prostate metastatic LLT
    Population Age: Adults, Elderly Gender: Male
    Trial protocol: IT (Prematurely Ended) ES (Ongoing) FR (Prematurely Ended)
    Trial results: (No results available)
    EudraCT Number: 2011-005334-20 Sponsor Protocol Number: MO28047 Start Date*: 2012-02-23
    Sponsor Name:F. Hoffmann-La Roche Ltd.
    Full Title: A multicenter, open-label, single-arm study of pertuzumab in combination with trastuzumab and a taxane in first line treatment of patients with HER2- positive advanced (metastatic or locally recurr...
    Medical condition: Advanced breast cancer (metastatic or locally recurrent)
    Disease: Version SOC Term Classification Code Term Level
    20.0 10029104 - Neoplasms benign, malignant and unspecified (incl cysts and polyps) 10065430 HER-2 positive breast cancer PT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: AT (Completed) FI (Completed) FR (Completed) ES (Completed) SI (Completed) GB (Completed) NL (Completed) DE (Completed) BE (Completed) HU (Completed) PT (Completed) GR (Completed) SE (Completed) IT (Completed) EE (Completed) LT (Completed) PL (Completed)
    Trial results: View results
    EudraCT Number: 2008-005872-29 Sponsor Protocol Number: MORAb-003-004 Start Date*: 2009-09-24
    Sponsor Name:Eisai Limited
    Full Title: A Randomized, Double-blind, Placebo-Controlled, Phase 3 Study to Assess the Efficacy and Safety of Weekly Farletuzumab (MORAb-003) in Combination with Carboplatin and Taxane in Subjects with Plati...
    Medical condition: First relapse of platinum-sensitive non-mucinous epithelial ovarian cancer including primary peritoneal or fallopian tube malignancies
    Disease: Version SOC Term Classification Code Term Level
    14.0 10029104 - Neoplasms benign, malignant and unspecified (incl cysts and polyps) 10033160 Ovarian epithelial cancer recurrent PT
    Population Age: Adults, Elderly Gender: Female
    Trial protocol: NL (Prematurely Ended) PT (Prematurely Ended) BE (Prematurely Ended) GB (Prematurely Ended) ES (Prematurely Ended) HU (Prematurely Ended) IT (Prematurely Ended) DE (Prematurely Ended) AT (Prematurely Ended) FR (Completed) GR (Prematurely Ended)
    Trial results: View results
    EudraCT Number: 2008-004171-21 Sponsor Protocol Number: L00070IN305B0 Start Date*: 2009-03-18
    Sponsor Name:PIERRE FABRE MEDICAMENT
    Full Title: Ensayo clínico en fase III de vinflunina más capecitabina frente a sólo capecitabina en pacientes con cáncer de mama avanzado previamente tratados con o resistentes a una antraciclina y que sean re...
    Medical condition: Cáncer de mama metastásico Breast cancer metastatic
    Disease: Version SOC Term Classification Code Term Level
    11.1 10055113 LLT
    Population Age: Adults, Elderly Gender: Female
    Trial protocol: ES (Prematurely Ended) FR (Completed) CZ (Completed) EE (Completed) IT (Prematurely Ended) GB (Prematurely Ended) BE (Completed) HU (Prematurely Ended) BG (Completed)
    Trial results: View results
    EudraCT Number: 2007-002083-98 Sponsor Protocol Number: TL139202 Start Date*: 2008-08-19
    Sponsor Name:Taxolog, Inc.
    Full Title: A Phase II Study of Milataxel (TL139) Administered Orally or Intravenously in Taxane Naïve Patients with Metastatic Breast Cancer.
    Medical condition: Taxane-naïve patients with metastatic breast cancer that is considered to be taxane sensitive.
    Disease: Version SOC Term Classification Code Term Level
    9.1 10027475 Metastatic breast cancer LLT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: HU (Prematurely Ended)
    Trial results: (No results available)
    EudraCT Number: 2010-018501-10 Sponsor Protocol Number: BAY43-9006/12444 Start Date*: 2011-03-23
    Sponsor Name:Bayer HealthCare AG
    Full Title: A Phase III Randomized, Double blind, Placebo-controlled Trial Comparing Capecitabine Plus Sorafenib Versus Capecitabine Plus Placebo in the Treatment of Locally Advanced or Metastatic HER2-Negativ...
    Medical condition: Locally advanced or metastatic HER2-negative breast cancer.
    Disease: Version SOC Term Classification Code Term Level
    17.0 100000004864 10004244 Benign breast neoplasm NOS LLT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: BE (Completed) DE (Completed) GB (Completed) AT (Completed) CZ (Completed) IE (Completed) ES (Completed) HU (Completed) IT (Completed) GR (Completed) SE (Completed)
    Trial results: View results
    EudraCT Number: 2004-000696-34 Sponsor Protocol Number: 927E-PRT007 Start Date*: 2004-11-02
    Sponsor Name:Daiichi Pharmaceutical Co., Ltd
    Full Title: A Phase II study of DJ-927 administered orally once every three weeks as second line therapy to subjects with locally advanced or metastatic non-small cell lung cancer (NSCLC) after failure of a pl...
    Medical condition: locally advanced or metastatic non small cell lung cancer following previous failure of a platinum-based non-taxane regimen
    Disease:
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: HU (Completed)
    Trial results: View results
    EudraCT Number: 2004-001457-28 Sponsor Protocol Number: CAM203 Start Date*: 2004-09-09
    Sponsor Name:CELL THERAPEUTICS EUROPE
    Full Title: Phase II open label study of CT-2106 as a single agent in patients with advanced metastatic ovarian cancer who have failed one prior platinum and taxane based regimen
    Medical condition: Treatment of patients with advanced ovarian cancer who have failed one prior platinum and taxane based regimen
    Disease: Version SOC Term Classification Code Term Level
    6.1 10057529 PT
    Population Age: Adults, Elderly Gender: Female
    Trial protocol: IT (Completed) GB (Completed)
    Trial results: (No results available)
    EudraCT Number: 2008-005180-33 Sponsor Protocol Number: CNTO328STM2001 Start Date*: 2009-02-09
    Sponsor Name:Centocor B.V.
    Full Title: A Phase 1/2, Multiple-dose, Dose-escalation Study to Assess the Safety, Efficacy, and Pharmacokinetics of Intravenous CNTO 328, an Anti-interleukin 6 (IL-6) Monoclonal Antibody, in Subjects with So...
    Medical condition: Malignant solid tumors
    Disease: Version SOC Term Classification Code Term Level
    9.1 10065147 Malignant solid tumor LLT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: FR (Completed) ES (Completed) GB (Completed) BE (Completed)
    Trial results: View results
    EudraCT Number: 2006-003085-34 Sponsor Protocol Number: TCD6945 Start Date*: 2006-10-05
    Sponsor Name:sanofi-aventis recherche & developpement
    Full Title: A Dose-escalating, Multicenter, Single arm, Open-label Study of XRP6258 in combination with capecitabine (Xeloda®), in patients with metastatic breast cancer with disease progressing after anthracy...
    Medical condition: Metastatic Breast Cancer
    Disease: Version SOC Term Classification Code Term Level
    8.1 10055113 Breast cancer metastatic LLT
    Population Age: Adults, Elderly Gender: Female
    Trial protocol: BE (Completed)
    Trial results: View results
    EudraCT Number: 2006-006474-21 Sponsor Protocol Number: TCD6511 Start Date*: 2007-03-08
    Sponsor Name:sanofi-aventis recherche et développement
    Full Title: A dose-escalating, multicenter, single arm, open-label study of XRP9881 in combination with capecitabine (Xeloda®), in metastatic breast cancer patients with disease progressing after anthracycline...
    Medical condition: Metastatic Breast Cancer
    Disease: Version SOC Term Classification Code Term Level
    8.1 10055113 Breast cancer metastatic LLT
    Population Age: Adults, Elderly Gender: Female
    Trial protocol: FR (Completed)
    Trial results: View results
    EudraCT Number: 2009-016338-29 Sponsor Protocol Number: GINECO-BR107 Start Date*: 2009-11-16
    Sponsor Name:ARCAGY
    Full Title: Essai randomisé multicentrique de phase III comparant la poursuite du traitement d’entretien par l’association bevacizumab + taxane versus remplacement par bevacizumab + exemestane chez des patient...
    Medical condition: Metastatic breast cancer
    Disease:
    Population Age: Adults, Elderly Gender: Female
    Trial protocol: FR (Completed)
    Trial results: View results
    EudraCT Number: 2004-005181-20 Sponsor Protocol Number: CEPO906A2303 Start Date*: 2006-05-19
    Sponsor Name:Novartis Pharma Services AG
    Full Title: A randomized, parallel group, open-label, active controlled, multicenter Phase III trial of Patupilone (EPO906) versus pegylated liposomal doxorubicin (Doxil/Caelyx) in taxane/platinum refractory/r...
    Medical condition: Approximately 75% of women with ovarian cancer present advanced disease. Survival is highly dependent on the stage of disease at the initiation of treatment. Favorable prognostic factors include yo...
    Disease:
    Population Age: Adults, Elderly Gender: Female
    Trial protocol: GB (Completed) ES (Completed) FI (Completed) DK (Completed) HU (Completed) GR (Completed) IT (Completed) IE (Completed)
    Trial results: View results
    EudraCT Number: 2010-021425-13 Sponsor Protocol Number: 212082PCR3001 Start Date*: 2011-02-10
    Sponsor Name:Janssen-Cilag International NV
    Full Title: An Open Label Study of Abiraterone Acetate in Subjects with Metastatic Castration-Resistant Prostate Cancer Who Have Progressed After Taxane-Based Chemotherapy
    Medical condition: Metastatic Castration-Resistant Prostate Cancer (PCR)
    Disease: Version SOC Term Classification Code Term Level
    14.0 10029104 - Neoplasms benign, malignant and unspecified (incl cysts and polyps) 10036909 Prostate cancer metastatic PT
    Population Age: Adults, Elderly Gender: Male
    Trial protocol: CZ (Completed) HU (Completed) ES (Completed) IT (Completed) LT (Prematurely Ended) DK (Completed) GR (Completed)
    Trial results: View results
    EudraCT Number: 2006-006950-81 Sponsor Protocol Number: KTN32313R Start Date*: 2007-09-25
    Sponsor Name:BioNumerik Pharmaceuticals, Inc.
    Full Title: A PHASE 3 STUDY OF SAFETY AND EFFICACY OF KARENITECIN VERSUS TOPOTECAN ADMINISTERED FOR 5 CONSECUTIVE DAYS EVERY 3 WEEKS IN PATIENTS WITH ADVANCED EPITHELIAL OVARIAN CANCER
    Medical condition: advanced epithelial ovarian cancer
    Disease: Version SOC Term Classification Code Term Level
    9.1 10066697 Ovarian cancer recurrent LLT
    Population Age: Adults, Elderly Gender: Female
    Trial protocol: DE (Prematurely Ended) HU (Prematurely Ended) LT (Prematurely Ended) PL (Prematurely Ended)
    Trial results: (No results available)
    EudraCT Number: 2016-003459-31 Sponsor Protocol Number: 2016/816 Start Date*: 2016-10-10
    Sponsor Name:Helse Bergen, Haukeland University Hospital
    Full Title: Treatment of patients with advanced breast cancer harboring TP53 mutations with dose-dense cyclophosphamide - the p53 trial
    Medical condition: Locally advanced breast cancer and metastatic breast cancer
    Disease:
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: NO (Ongoing)
    Trial results: (No results available)
    EudraCT Number: 2017-002961-23 Sponsor Protocol Number: ODO-TE-B301 Start Date*: Information not available in EudraCT
    Sponsor Name:Odonate Therapeutics, Inc.
    Full Title: A Multinational, Multicenter, Randomized, Phase 3 Study of Tesetaxel plus a Reduced Dose of Capecitabine versus Capecitabine Alone in Patients with HER2 Negative, Hormone Receptor Positive, Locally...
    Medical condition: Patients with Breast Cancer
    Disease:
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: CZ (Prematurely Ended) HU (Completed) ES (Prematurely Ended) GB (GB - no longer in EU/EEA) AT (Prematurely Ended) DE (Completed) BE (Prematurely Ended) FR (Prematurely Ended) PL (Prematurely Ended) IT (Prematurely Ended)
    Trial results: (No results available)
    EudraCT Number: 2005-004257-96 Sponsor Protocol Number: 0002A3-200-EU Start Date*: 2006-02-20
    Sponsor Name:Xanthus Pharmaceuticals Inc
    Full Title: Phase II Study with Symadex (C-1311) in Women with Metastatic Breast Cancer after Anthracycline and Taxane Failure
    Medical condition: Breast Cancer
    Disease:
    Population Age: Adults, Elderly Gender: Female
    Trial protocol: GB (Completed)
    Trial results: (No results available)
    Download Options:
    Number of Trials to download:
    Download Content:
    Download Format:
    Note, where multi-state trials are shown in search results, selecting "Full Trial details" will download full information for each of the member states/countries involved in the trial.
    1  2  3  4  5  6  7  8  9  Next» Last»»
    Query did not match any studies.
    For support, Contact us.
    The status and protocol content of GB trials is no longer updated since 1 January 2021. For the UK, as of 31 January 2021, EU Law applies only to the territory of Northern Ireland (NI) to the extent foreseen in the Protocol on Ireland/NI. Legal notice
    As of 31 January 2023, all EU/EEA initial clinical trial applications must be submitted through CTIS . Updated EudraCT trials information and information on PIP/Art 46 trials conducted exclusively in third countries continues to be submitted through EudraCT and published on this website.

    European Medicines Agency © 1995-Mon May 20 01:03:57 CEST 2024 | Domenico Scarlattilaan 6, 1083 HS Amsterdam, The Netherlands
    EMA HMA